Hormone therapy for patients with advanced or recurrent endometrial cancer |
| |
| Affiliation: | 1. Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC;2. Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan, ROC;3. Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC;4. Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC;5. Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC;6. Department of Obstetrics and Gynecology, Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan, ROC;7. Department of Obstetrics and Gynecology, Taipei City Hospital, Taipei, Taiwan, ROC;8. Foundation of Gynecological Cancer, Taipei, Taiwan, ROC;9. Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC;10. Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC;11. Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, ROC |
| |
| Abstract: | The “gold standard” treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15–20% and nearly ≤10%, respectively. This review is focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent endometrial cancers. |
| |
| Keywords: | advanced endometrial cancer estrogen hormone therapy progesterone recurrent endometrial cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
